SOD1 Plasma Level as a Biomarker for Therapeutic Failure in Cutaneous Leishmaniasis
SOD1 Plasma Level as a Biomarker for Therapeutic Failure in Cutaneous Leishmaniasis
复制标题
DOI：
10.1093/infdis/jiu087
复制
发表时间：
2014-07-15
影响因子：
6.4
通讯作者：
Van Weyenbergh, Johan
中科院分区：
文献类型：
--
作者：
Khouri, Ricardo;Santos, Gilvaneia Silva;Van Weyenbergh, Johan
我们发现，增加血浆超氧化物歧化酶1（SOD 1）水平的五价锑治疗巴西利什曼原虫引起的皮肤利什曼病的失败有统计学意义的预测。在亚马逊利什曼原虫感染的患者中，宿主SOD 1水平可用于区分局部和耐药的弥漫性皮肤利什曼病。使用原位转录组学（nCounter），我们证明了宿主SOD 1和干扰素α/β信使RNA（mRNA）水平之间的显着正相关性，以及宿主SOD 1和寄生虫SOD 2/4 mRNA水平之间的王国间相关性。在人巨噬细胞中，用SOD 1体外处理增加了寄生虫负荷，并诱导了弥漫性皮肤利什曼病样形态。因此，SOD 1是局部和弥漫性皮肤利什曼病的临床相关生物标志物和治疗靶点。
We show that increased plasma superoxide dismutase 1 (SOD1) levels are statistically significant predictors of the failure of pentavalent antimony treatment for cutaneous leishmaniasis caused by Leishmania braziliensis. In Leishmania amazonensis-infected patients, host SOD1 levels can be used to discriminate between localized and drug-resistant diffuse cutaneous leishmaniasis. Using in situ transcriptomics (nCounter), we demonstrate a significant positive correlation between host SOD1 and interferon alpha/beta messenger RNA (mRNA) levels, as well as interkingdom correlation between host SOD1 and parasite SOD2/4 mRNA levels. In human macrophages, in vitro treatment with SOD1 increases the parasite burden and induces a diffuse cutaneous leishmaniasis-like morphology. Thus, SOD1 is a clinically relevant biomarker and a therapeutic target in both localized and diffuse cutaneous leishmaniasis.